Stewing volatility in stock requests, API effects, the parent company of healthtech unicorn PharmEasy, has withdrawn its draft red herring prospectus (DRHP) that it had filed with the Securities and Exchange Board of India (Sebi), the company informed its shareholders in a note. The pre-IPO draft papers, which were filed
Indian medicine and medical services incipiency PharmEasy is in addresses with investors to raise $ 200 million, but at a valuation that could be 15% or indeed 25% lower than last time’s $5.1 billion, two people with direct knowledge of deal addresses told Reuters. Motioning growing stress in India’s incipiency
PharmEasy vendor network can deploy Unicommerce, a state-of-the-art technology platform, to manage the rising order volume. PharmEasy, India’s leading consumer healthcare’ super app'( furnishing online drugstore, OTC, teleconsultation, and diagnostics services), has blazoned its association with Unicommerce, an intertwined SaaS platform for post-purchase experience operation of consumers to further streamline
API Holdings, the parent firm of PharmEasy, has got clearance from markets regulator Securities and Exchange Board of India for the online pharmacy’s initial public offering. Sebi’s nod for PharmEasy’s parent’s IPO comes at a time when new-age companies are seeing a steady drop in their share prices after having
A new-age online pharmacy, PharmEasy feel the pressure of broader market rout, may have to readjust its valuation it was aiming for through a public offering. in the grey market, its shares are currently being traded anywhere between Rs 70 and Rs 80, significantly lower than over Rs 100 earlier
